Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Abroad (travel likely)RecruitingPHASE2
Conditions
Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1 · Anti-VEGFR
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Principal Investigator (Lai-ping Zhong, MD, PhD)
Study leads
Lai-ping Zhong, MD, PhD
Principal Investigator
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine